N/A
N/A ( 0% ) N/A
Market Data
| Open | N/A |
| Previous Close | $0.00 |
| Volume | N/A |
| Market Cap | N/A |
| Day Range | N/A - N/A |
| 52 Week Range | $0.00 - $0.10 |
| Shares Outstanding | N/A |
| Change % | 0% |
| Net Change | N/A |
| Insider Ownership | N/A |
| Exchange | OTC |
| Sector | Miscellaneous |
| Industry | |
| IPO Year | |
| Country | |
| Under Writer | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased: 683,572.00
| Date | Type | Amount Purchased | Purchaser |
|---|---|---|---|
| 2024-06-28 | Sale | -200000.00 | Windham-Bannister Susan Richards |
| 2024-06-28 | Sale | -200000.00 | HAMILTON JOHN F |
| 2024-06-28 | Sale | -250000.00 | Jafri Hasan |
| 2024-06-28 | Buy | 714286.00 | Patzer Eric |
| 2024-06-28 | Buy | 714286.00 | Truong Vu |
| 2023-09-19 | Sale | -20000.00 | Jafri Hasan |
| 2023-09-19 | Sale | -15000.00 | Windham-Bannister Susan Richards |
| 2023-09-19 | Sale | -15000.00 | Patzer Eric |
| 2023-09-19 | Sale | -15000.00 | HAMILTON JOHN F |
| 2023-09-19 | Sale | -30000.00 | Truong Vu |
Institutional Ownership
Total Market Value $ 0.00
| Symbol | Issuer Name | Market Value ↓ | Share Quantity | |
|---|---|---|---|---|
| No records found. | ||||
SEC Fillings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 4 | Insider transactions | 1 | Jun 28, 2024 |
| 4 | Insider transactions | 1 | Jun 28, 2024 |
| 4 | Insider transactions | 1 | Jun 28, 2024 |
| 4 | Insider transactions | 1 | Jun 28, 2024 |
| 4 | Insider transactions | 1 | Jun 28, 2024 |
| 8-k | 8K-related | 14 | Jun 27, 2024 |
Latest News
Aridis Pharmaceuticals
N/A
N/A 0%
(NASDAQ: ARDS)
Company Overview Listen to Overview
Value Proposition Listen to Value Proposition
Investor Presentation
Investment Highlights Listen to Investment Highlights
- Unique, novel approach using human-derived mAbs to treat infectious diseases
- Addressing $1B+ opportunity with lead drug candidate AR-301
-
Addressing $2 billion market opportunity with its lead drug candidates AR-301 & AR-320
- AR-301: first of two planned Phase 3 trials; received agreement from FDA on single confirmatory Phase 3 study design in May 2023
- AR-501: met primary and secondary endpoints
- Received $1.9M grant from the Bill & Melinda Gates Foundation to evaluate inhaled monoclonal antibodies against influenza and COVID-19
- Received $12.5M in grant and equity funding from the Cystic Fibrosis Foundation to develop treatment for CF patients with pneumonia
-
World-class team of senior executives:
- CEO, Director – Vu Truong; Medimmune, Aviron
- Chief Medical Officer – Hasan Jafri; AstraZeneca, Medimmune
- Director - Robert Rufolo- Wyeth/Pfizer; Craig Gibbs- Gilead; Eric Patzer- Genentech
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Aridis Pharmaceuticals, Inc. (ARDS) is a client of RedChip Companies, Inc. ARDS agreed to pay RedChip Companies, Inc. a $8,000 monthly cash fee, beginning in February 26th, 2022 and 5000 restricted common shares of ARDS stock for 6 months of RedChip investor awareness services.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.